About Recombine
Recombine is a Healthcare company based in New York (United States) founded in 2011, and was acquired by CooperSurgical in May 2016. Clinical genetic testing and counseling services are provided. Recombine has raised $12.07 million across 3 funding rounds from investors including FirstMark, Vast Ventures and Zach Weinberg. Recombine offers products and services including Paragard, Endosee Advance System, and RUMI II. Its focus areas include Life Sciences, Women Health, In Vitro Diagnostic Tests and Prenatal. Its legal entity is CooperSurgical, Inc. Its competitors include Natera, Invitae and Helix; 3 of its 3 listed competitors have raised funding.
Company details
Recombine was founded in 2011 in New York, United States, and operates in the genetic testing sector. Clinical services are offered, including CarrierMap for comprehensive carrier screening and ChromoMap for non-invasive prenatal chromosome analysis using maternal blood. Sample collection and genetic counseling are also managed to support testing processes. Operations focus on reducing risks associated with invasive procedures.
- Headquarters New York, United States
- Stage Acquired
- SectorsHealthcare
- Website recombine.com
- Social LinkedIn X Facebook Instagram YouTube
- Acquired by CooperSurgical (May 2016)
- Legal Name Coopersurgical, Inc.
- Total Equity Funding$12.07M (USD)
in 3 rounds
- Latest Funding Round$8.44M (USD), Series B
Jul 2016
- InvestorsFirstMark
& 5 more
- Acquired byCooperSurgical
(May 2016)
Products & Services of Recombine
Recombine offers a comprehensive portfolio of products and services, including Paragard, Endosee Advance System, and RUMI II.
Intrauterine device for long-term birth control.
Device for hysteroscopic visualization and diagnostics.
Surgical manipulator for uterine procedures.
Apps and channels of Recombine
its YouTube channel CooperSurgical Fertility Solutions has 57.7K subscribers and 30 videos.
Videos from Recombine
The most watched videos on Recombine's YouTube channel, CooperSurgical Fertility Solutions (57.7K subscribers). Click a video to play it here.
More on CooperSurgical Fertility Solutions.
Funding Insights of Recombine
Recombine has successfully raised a total of $12.07M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $8.44 million completed in July 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $12.07M
- Total Rounds 3
- Last Round Series B — $8.44M
- First Round $3.63M
(Feb 2014)
- Investors Count 5
All 3 funding rounds of Recombine with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2016 | $8.44M | Series B | – | – | – |
| Oct 2015 | $995,000 | Debt – Conventional | – | – | – |
| Feb 2014 | $3.63M | Series A | – | FirstMark |
6 investors in total: 3 institutional and 3 angel.
Investors in Recombine
Recombine has secured backing from 6 investors, including venture fund, angel, and institutional investors. Prominent investors backing the company include FirstMark, Vast Ventures and Zach Weinberg.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
US focused venture capital firm | vastvc.com | New York, United States | ||
Early-stage venture capital is invested in tech startups across sectors. | 1987 | firstmark.com | New York, United States | |
Offers medical devices for fertility, contraception, and women's health care globally. | 1990 | coopersurgical.com | Trumbull, United States | |
ZW Zach Weinberg | Co-founder of Flatiron Health, angel investor in health tech and AI startups. | unknown_90ef06f30b0743c68 | ||
NT Nat Turner | Co-founder of Flatiron Health, active angel investor in health tech. | unknown_fe94238292d14eb59 | ||
VG Vivek Garipalli | Indian angel investor, co-founder of Clover Health, healthcare tech innovator | unknown_806f2da48d3246a58 |
Investor details for Recombine
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Recombine
4 dated milestones of Recombine across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Recombine is founded.
- Funding First funding round of $3.6M.
- Exit Acquired by CooperSurgical.
- Funding Latest funding round, Series B, of $8.4M.
Competitors of Recombine
Recombine has 3 listed competitors in our database, 3 of them funded. They include Natera, Invitae and Helix.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health | |
| invitae.com | 2010 | San Francisco, United States | $189.56M | 1,700 | Home-based genetic tests for detecting diseases are provided to individuals. | |
| helix.com | 2015 | San Francisco, United States | $435M | Genomic database for clinical research is provided. |
Detailed competitors of Recombine
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Recombine
Websites that share an audience with Recombine (recombine.com).
Websites whose visitors overlap most with Recombine. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| sherpaa.com | 100% | View details | |||
| geneplanet.com | 98% | 54.7K | #352,885 | View details | |
climb.org.uk | climb.org.uk | 93% | – | ||
| correlagen.com | 88% | View details | |||
| phgfoundation.org | 87% | 15.8K | #1,675,344 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 19 similar websites and full traffic analytics for Recombine
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 19 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Recombine (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Recombine
Complete news archive for Recombine
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Recombine
Recombine was founded in 2011 and raised its 1st funding round 3 years after it was founded.
Recombine is headquartered in New York, United States. It is registered at New York, New York, United States.
Recombine is a funded company, having raised a total of $12.07M across 3 funding rounds to date. The company's 1st funding round was a Series A of $3.63M, raised on Feb 2014.
Recombine was founded in 2011 in New York, United States, and operates in the genetic testing sector. Clinical services are offered, including CarrierMap for comprehensive carrier screening and ChromoMap for non-invasive prenatal chromosome analysis using maternal blood. Sample collection and genetic counseling are also managed to support testing processes. Operations focus on reducing risks associated with invasive procedures.
Recombine offers Paragard, Endosee Advance System, and RUMI II.
Recombine has 6 investors. Key investors include FirstMark, Vast Ventures, Zach Weinberg, Nat Turner, and Vivek Garipalli.
Recombine operates through Coopersurgical, Inc..
Yes. Recombine was acquired by CooperSurgical in May 2016.